New Therapies to Modulate Post-infarction Inflammatory Alterations in the Myocardium: State of the art and Forthcoming Applications.

New Therapies to Modulate Post-infarction Inflammatory Alterations in the Myocardium: State of the art and Forthcoming Applications. Curr Radiopharm. 2020 Dec 10;: Authors: Clerc OF, Haaf P, Buechel RR, Gaemperli O, Zellweger MJ Abstract Acute myocardial infarction (AMI) is a major cause of morbidity and mortality worldwide. AMI causes a necrosis of cardiac cells and triggers a complex inflammatory response, affecting infarct size, cardiac function and clinical outcomes. This inflammatory response can be divided into 3 phases: 1) the pro-inflammatory phase, in which the release of damage-associated molecular patterns from necrotic cells triggers the secretion of pro-inflammatory mediators and attracts immune cells to clean the debris, further damaging viable myocardium, 2) the reparative phase, in which antiinflammatory signals activate immune-modulating cells and trigger the production of a stable scar, 3) the maturation phase, in which inflammatory and fibrotic signals are suppressed, but may persist, leading to left ventricular adverse remodelling. Thus, the inflammatory response is an appealing therapeutic target to improve outcomes of patients AMI. Numerous anti-inflammatory therapies have shown promise in animal models, but translation to human trials exhibited limited benefit. Glucocorticoids and non-steroidal anti-inflammatory drugs showed signals of harm due to their nonspecific effects. Other broad inhibitors, e.g. methotre...
Source: Current Radiopharmaceuticals - Category: Radiology Tags: Curr Radiopharm Source Type: research